Journal Article
. 2008 Dec; 105(51):20410-5.
doi: 10.1073/pnas.0810114105.

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Jianda Yuan 1 Sacha Gnjatic  Hao Li  Sarah Powel  Humilidad F Gallardo  Erika Ritter  Geoffrey Y Ku  Achim A Jungbluth  Neil H Segal  Teresa S Rasalan  Gregor Manukian  Yinyan Xu  Ruth-Ann Roman  Stephanie L Terzulli  Melanie Heywood  Evelina Pogoriler  Gerd Ritter  Lloyd J Old  James P Allison  Jedd D Wolchok  
  • PMID: 19074257
  •     32 References
  •     159 citations


Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell responses and induce durable clinical responses in patients with metastatic melanoma. The functional impact of anti-CTLA-4 therapy on human immune responses is still unclear. To explore this, we analyzed immune-related adverse events and immune responses in metastatic melanoma patients treated with ipilimumab, a fully human anti-CTLA-4 monoclonal antibody. Fifteen patients were selected on the basis of availability of suitable specimens for immunologic monitoring, and eight of these showed evidence of clinical benefit. Five of the eight patients with evidence of clinical benefit had NY-ESO-1 antibody, whereas none of seven clinical non-responders was seropositive for NY-ESO-1. All five NY-ESO-1 seropositive patients had clearly detectable CD4(+) and CD8(+) T cells against NY-ESO-1 following treatment with ipilimumab. One NY-ESO-1 seronegative clinical responder also had a NY-ESO-1 CD4(+) and CD8(+) T cell response, possibly related to prior vaccination with NY-ESO-1. Among five clinical non-responders analyzed, only one had a NY-ESO-1 CD4(+) T cell response and this patient did not have detectable anti-NY-ESO-1 antibody. Overall, NY-ESO-1-specific T cell responses increased in frequency and functionality during anti-CTLA-4 treatment, revealing a polyfunctional response pattern of IFN-gamma, MIP-1beta and TNF-alpha. We therefore suggest that CTLA-4 blockade enhanced NY-ESO-1 antigen-specific B cell and T cell immune responses in patients with durable objective clinical responses and stable disease. These data provide an immunologic rationale for the efficacy of anti-CTLA-4 therapy and call for immunotherapeutic designs that combine NY-ESO-1 vaccination with CTLA-4 blockade.

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
F Stephen Hodi, Marcus Butler, +17 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Feb 22; 105(8). PMID: 18287062    Free PMC article.
Highly Cited.
CTLA-4-Mediated inhibition of early events of T cell proliferation.
M C Brunner, C A Chambers, +3 authors, J P Allison.
J Immunol, 1999 May 07; 162(10). PMID: 10229815
Highly Cited.
Cancer/testis antigens, gametogenesis and cancer.
Andrew J G Simpson, Otavia L Caballero, +2 authors, Lloyd J Old.
Nat Rev Cancer, 2005 Jul 22; 5(8). PMID: 16034368
Highly Cited. Review.
Polyfunctional T cell responses are a hallmark of HIV-2 infection.
Melody G Duvall, Melissa L Precopio, +6 authors, Richard A Koup.
Eur J Immunol, 2008 Jan 18; 38(2). PMID: 18200635    Free PMC article.
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Ryohei Kawabata, Hisashi Wada, +17 authors, Eiichi Nakayama.
Int J Cancer, 2007 Feb 06; 120(10). PMID: 17278093
B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
B Salomon, D J Lenschow, +4 authors, J A Bluestone.
Immunity, 2000 May 05; 12(4). PMID: 10795741
Highly Cited.
CTLA-4: a negative regulator of autoimmune disease.
N J Karandikar, C L Vanderlugt, +2 authors, J A Bluestone.
J Exp Med, 1996 Aug 01; 184(2). PMID: 8760834    Free PMC article.
Highly Cited.
CTLA-4 ligation blocks CD28-dependent T cell activation.
T L Walunas, C Y Bakker, J A Bluestone.
J Exp Med, 1996 Jun 01; 183(6). PMID: 8676075    Free PMC article.
Highly Cited.
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
Antoni Ribas, Douglas C Hanson, +6 authors, Jesus Gomez-Navarro.
Oncologist, 2007 Aug 04; 12(7). PMID: 17673618
Checkpoint blockade in cancer immunotherapy.
Alan J Korman, Karl S Peggs, James P Allison.
Adv Immunol, 2006 May 30; 90. PMID: 16730267    Free PMC article.
Highly Cited. Review.
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
Stephanie G Downey, Jacob A Klapper, +12 authors, Steven A Rosenberg.
Clin Cancer Res, 2007 Nov 06; 13(22 Pt 1). PMID: 17982122    Free PMC article.
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
A van Elsas, R P Sutmuller, +8 authors, J P Allison.
J Exp Med, 2001 Aug 22; 194(4). PMID: 11514604    Free PMC article.
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Ian D Davis, Weisan Chen, +25 authors, Jonathan S Cebon.
Proc Natl Acad Sci U S A, 2004 Jul 15; 101(29). PMID: 15252201    Free PMC article.
Highly Cited.
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Kazuhide Tsuji, Toshitada Hamada, +12 authors, Keiji Iwatsuki.
Cancer Immunol Immunother, 2008 Mar 04; 57(10). PMID: 18311489
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
T-cell quality in memory and protection: implications for vaccine design.
Robert A Seder, Patricia A Darrah, Mario Roederer.
Nat Rev Immunol, 2008 Mar 08; 8(4). PMID: 18323851
Highly Cited. Review.
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
F Stephen Hodi, Martin C Mihm, +14 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2003 Apr 17; 100(8). PMID: 12682289    Free PMC article.
Highly Cited.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Giao Q Phan, James C Yang, +14 authors, Steven A Rosenberg.
Proc Natl Acad Sci U S A, 2003 Jun 27; 100(14). PMID: 12826605    Free PMC article.
Highly Cited.
Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, +7 authors, Elke Jäger.
Cancer Res, 2005 May 04; 65(9). PMID: 15867394
Tumor antigen expression in melanoma varies according to antigen and stage.
Catherine Barrow, Judy Browning, +4 authors, Jonathan Cebon.
Clin Cancer Res, 2006 Feb 10; 12(3 Pt 1). PMID: 16467087
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.
A A Jungbluth, Y T Chen, +7 authors, L J Old.
Int J Cancer, 2001 May 15; 92(6). PMID: 11351307
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
S Read, V Malmström, F Powrie.
J Exp Med, 2000 Jul 19; 192(2). PMID: 10899916    Free PMC article.
Highly Cited.
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
M F Krummel, J P Allison.
J Exp Med, 1995 Aug 01; 182(2). PMID: 7543139    Free PMC article.
Highly Cited.
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.
Danila Valmori, Frédéric Lévy, +8 authors, Maha Ayyoub.
Clin Immunol, 2006 Oct 27; 122(2). PMID: 17064965
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Ajay V Maker, Peter Attia, Steven A Rosenberg.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301685    Free PMC article.
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
Melissa L Precopio, Michael R Betts, +11 authors, Richard A Koup.
J Exp Med, 2007 May 31; 204(6). PMID: 17535971    Free PMC article.
Highly Cited.
Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
Sylvia Adams, David W O'Neill, +21 authors, Nina Bhardwaj.
J Immunol, 2008 Jun 21; 181(1). PMID: 18566444    Free PMC article.
NY-ESO-1: review of an immunogenic tumor antigen.
Sacha Gnjatic, Hiroyoshi Nishikawa, +6 authors, Lloyd J Old.
Adv Cancer Res, 2006 Jul 25; 95. PMID: 16860654
Highly Cited. Review.
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Akiko Uenaka, Hisashi Wada, +18 authors, Eiichi Nakayama.
Cancer Immun, 2007 Apr 20; 7. PMID: 17441676    Free PMC article.
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.
Begoña Comin-Anduix, Yohan Lee, +13 authors, Antoni Ribas.
J Transl Med, 2008 May 03; 6. PMID: 18452610    Free PMC article.
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
Chrysoula I Liakou, Ashish Kamat, +5 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2008 Sep 27; 105(39). PMID: 18818309    Free PMC article.
Highly Cited.
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
Hong Chen, Chrysoula I Liakou, +8 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2009 Feb 10; 106(8). PMID: 19202079    Free PMC article.
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Jianda Yuan, Geoffrey Y Ku, +14 authors, Jedd D Wolchok.
Cancer Immun, 2009 Jun 06; 9. PMID: 19496531    Free PMC article.
Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Antoni Ribas, Begoña Comin-Anduix, +15 authors, Jesus Gomez-Navarro.
Clin Cancer Res, 2009 Oct 01; 15(19). PMID: 19789309    Free PMC article.
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.
Yun Lin, Humilidad F Gallardo, +10 authors, Jianda Yuan.
Cytotherapy, 2009 Nov 12; 11(7). PMID: 19903103    Free PMC article.
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
William Humphries, Jun Wei, John H Sampson, Amy B Heimberger.
Neurosurg Clin N Am, 2009 Dec 01; 21(1). PMID: 19944972    Free PMC article.
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
Jianda Yuan, David B Page, +14 authors, Jedd D Wolchok.
Cancer Immun, 2010 Jan 08; 10. PMID: 20052966    Free PMC article.
Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.
Yi-chi M Kong, Wei-Zen Wei, Yaron Tomer.
Ann N Y Acad Sci, 2010 Feb 12; 1183. PMID: 20146718    Free PMC article.
Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy.
G Elizabeth Pluhar, Patrick T Grogan, +9 authors, John R Ohlfest.
Vaccine, 2010 Mar 04; 28(19). PMID: 20197146    Free PMC article.
Therapeutic antibodies, vaccines and antibodyomes.
Dimiter S Dimitrov.
MAbs, 2010 Apr 20; 2(3). PMID: 20400863    Free PMC article.
Directing dendritic cell immunotherapy towards successful cancer treatment.
Rachel Lubong Sabado, Nina Bhardwaj.
Immunotherapy, 2010 May 18; 2(1). PMID: 20473346    Free PMC article.
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.
Richard J O'Reilly, Tao Dao, +2 authors, Ekaterina Doubrovina.
Semin Immunol, 2010 Jun 12; 22(3). PMID: 20537908    Free PMC article.
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Swagatam Ray, Arvind Chhabra, +11 authors, UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.
Clin Immunol, 2010 Jun 16; 136(3). PMID: 20547105    Free PMC article.
Modulation of CTLA-4 and GITR for cancer immunotherapy.
Francesca Avogadri, Jianda Yuan, +2 authors, Jedd D Wolchok.
Curr Top Microbiol Immunol, 2010 Jun 22; 344. PMID: 20563707    Free PMC article.
Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancer.
Brett B Maricque, Jens C Eickhoff, Douglas G McNeel.
Prostate, 2010 Jul 16; 71(2). PMID: 20632317    Free PMC article.
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.
Brian A Ginsberg, Humilidad F Gallardo, +13 authors, Jedd D Wolchok.
Clin Cancer Res, 2010 Jul 22; 16(15). PMID: 20647477    Free PMC article.
Interface of signal transduction inhibition and immunotherapy in melanoma.
Amber L Shada, Kerrington R Molhoek, Craig L Slingluff.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693848    Free PMC article.
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
Margaret K Callahan, Jedd D Wolchok, James P Allison.
Semin Oncol, 2010 Nov 16; 37(5). PMID: 21074063    Free PMC article.
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
Amod A Sarnaik, Bin Yu, +9 authors, Jeffrey S Weber.
Clin Cancer Res, 2010 Nov 26; 17(4). PMID: 21106722    Free PMC article.
Regional treatment strategies for in-transit melanoma metastasis.
Ryan S Turley, Amanda K Raymond, Douglas S Tyler.
Surg Oncol Clin N Am, 2010 Nov 30; 20(1). PMID: 21111960    Free PMC article.
B7-h3 and its role in antitumor immunity.
Martin Loos, Dennis M Hedderich, Helmut Friess, Jörg Kleeff.
Clin Dev Immunol, 2010 Dec 04; 2010. PMID: 21127709    Free PMC article.
Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.
Timothy M Clay, Takuya Osada, +4 authors, H Kim Lyerly.
Immunol Res, 2010 Dec 08; 49(1-3). PMID: 21136201    Free PMC article.
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
Amy B Heimberger, John H Sampson.
Neuro Oncol, 2010 Dec 15; 13(1). PMID: 21149252    Free PMC article.
Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens.
Xi Zhao, Anamika Bose, +12 authors, Walter J Storkus.
Mol Ther, 2010 Dec 30; 19(4). PMID: 21189473    Free PMC article.
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
Heath A Smith, Brett B Maricque, +4 authors, Douglas G McNeel.
J Biomed Biotechnol, 2011 Jan 05; 2011. PMID: 21197272    Free PMC article.
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.
Eric Tran, Julie S Nielsen, +6 authors, Brad H Nelson.
PLoS One, 2011 Jan 05; 5(12). PMID: 21203522    Free PMC article.
Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.
Patrick A Ott, Sylvia Adams.
Immunotherapy, 2011 Feb 17; 3(2). PMID: 21322760    Free PMC article.
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.
Brian M Olson, Douglas G McNeel.
Cancer Immunol Immunother, 2011 Feb 26; 60(6). PMID: 21350948    Free PMC article.
The biology of cancer testis antigens: putative function, regulation and therapeutic potential.
Elisabetta Fratta, Sandra Coral, +6 authors, Michele Maio.
Mol Oncol, 2011 Mar 08; 5(2). PMID: 21376678    Free PMC article.
Highly Cited.
Enhanced sensitivity to IL-2 signaling regulates the clinical responsiveness of IL-12-primed CD8(+) T cells in a melanoma model.
Dominique N Lisiero, Horacio Soto, Linda M Liau, Robert M Prins.
J Immunol, 2011 Mar 25; 186(9). PMID: 21430221    Free PMC article.
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Larry D Anderson, Danielle R Cook, +3 authors, Stanley R Riddell.
Cancer Immunol Immunother, 2011 Apr 05; 60(7). PMID: 21461886    Free PMC article.
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Jianda Yuan, Brian Ginsberg, +11 authors, Jedd D Wolchok.
Cancer Immunol Immunother, 2011 Apr 06; 60(8). PMID: 21465316    Free PMC article.
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Rong Rong Huang, Jason Jalil, +10 authors, Antoni Ribas.
Clin Cancer Res, 2011 May 12; 17(12). PMID: 21558401    Free PMC article.
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.
Amy E Gilbert, Panagiotis Karagiannis, +16 authors, Sophia N Karagiannis.
PLoS One, 2011 May 12; 6(4). PMID: 21559411    Free PMC article.
Immunosuppressive tumor microenvironment in cervical cancer patients.
Sytse J Piersma.
Cancer Microenviron, 2011 Jun 01; 4(3). PMID: 21626415    Free PMC article.
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.
Takemasa Tsuji, Junko Matsuzaki, +5 authors, Sacha Gnjatic.
PLoS One, 2011 Aug 23; 6(8). PMID: 21858191    Free PMC article.
Adoptive T-cell therapy of melanoma using designer T-cell receptors.
Kim Margolin.
Curr Oncol Rep, 2011 Sep 21; 13(6). PMID: 21931938
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
Jianda Yuan, Matthew Adamow, +16 authors, Sacha Gnjatic.
Proc Natl Acad Sci U S A, 2011 Sep 22; 108(40). PMID: 21933959    Free PMC article.
Highly Cited.
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
Padmanee Sharma, Klaus Wagner, Jedd D Wolchok, James P Allison.
Nat Rev Cancer, 2011 Oct 25; 11(11). PMID: 22020206    Free PMC article.
Highly Cited. Review.
Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma.
Jun Zhou, Noah K Yuen, +4 authors, F Stephen Hodi.
Cancer Immunol Immunother, 2011 Oct 29; 61(5). PMID: 22033581    Free PMC article.
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Xiang-Yang Wang, Daming Zuo, Devanand Sarkar, Paul B Fisher.
Expert Opin Pharmacother, 2011 Nov 15; 12(17). PMID: 22077831    Free PMC article.
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.
Douglas G McNeel, Heath A Smith, +4 authors, Glenn Liu.
Cancer Immunol Immunother, 2012 Jan 03; 61(7). PMID: 22210552    Free PMC article.
Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes.
Evan W Newell, Natalia Sigal, +2 authors, Mark M Davis.
Immunity, 2012 Jan 24; 36(1). PMID: 22265676    Free PMC article.
Highly Cited.
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.
Polly Gregor, Q Daisy Huang, +2 authors, Michael J Morris.
Clin Genitourin Cancer, 2012 Jan 31; 10(2). PMID: 22284755    Free PMC article.
The secret ally: immunostimulation by anticancer drugs.
Lorenzo Galluzzi, Laura Senovilla, Laurence Zitvogel, Guido Kroemer.
Nat Rev Drug Discov, 2012 Feb 04; 11(3). PMID: 22301798
Highly Cited. Review.
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.
Yan-Ho Cheng, Elissa Wp Wong, C Yan Cheng.
Spermatogenesis, 2012 Feb 10; 1(3). PMID: 22319669    Free PMC article.
Unmasking the immune recognition of prostate cancer with CTLA4 blockade.
Serena S Kwek, Edward Cha, Lawrence Fong.
Nat Rev Cancer, 2012 Mar 02; 12(4). PMID: 22378189    Free PMC article.
Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.
Zhi-Chun Ding, Gang Zhou.
Clin Dev Immunol, 2012 Mar 09; 2012. PMID: 22400040    Free PMC article.
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
Kunle Odunsi, Junko Matsuzaki, +14 authors, Elke Jäger.
Proc Natl Acad Sci U S A, 2012 Mar 29; 109(15). PMID: 22454499    Free PMC article.
Highly Cited.
The role of regulatory T cells and TH17 cells in multiple myeloma.
Walter M T Braga, Djordje Atanackovic, Gisele W B Colleoni.
Clin Dev Immunol, 2012 Apr 11; 2012. PMID: 22489248    Free PMC article.
Therapeutic antibodies against cancer.
Mark J Adler, Dimiter S Dimitrov.
Hematol Oncol Clin North Am, 2012 Apr 24; 26(3). PMID: 22520975    Free PMC article.
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
Kris C Wood, David J Konieczkowski, +8 authors, David M Sabatini.
Sci Signal, 2012 May 17; 5(224). PMID: 22589389    Free PMC article.
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy.
Susan R Slovin.
Front Oncol, 2012 Jun 05; 2. PMID: 22662316    Free PMC article.
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy.
Zhi-Chun Ding, Lei Huang, +4 authors, Gang Zhou.
Blood, 2012 Aug 04; 120(11). PMID: 22859605    Free PMC article.
Evaluating cellular polyfunctionality with a novel polyfunctionality index.
Martin Larsen, Delphine Sauce, +3 authors, Guy Gorochov.
PLoS One, 2012 Aug 04; 7(7). PMID: 22860124    Free PMC article.
Introduction to monoclonal antibodies.
Jean-Pierre Mach.
Cancer Immun, 2012 Aug 17; 12. PMID: 22896756    Free PMC article.
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients.
Serena S Kwek, Vinh Dao, +5 authors, Lawrence Fong.
J Immunol, 2012 Sep 08; 189(7). PMID: 22956585    Free PMC article.
Advances in the development of cancer immunotherapies.
Jianjun Gao, Chantale Bernatchez, +2 authors, Patrick Hwu.
Trends Immunol, 2012 Oct 04; 34(2). PMID: 23031830    Free PMC article.
Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
Brian M Olson, Ewa Jankowska-Gan, +3 authors, Douglas G McNeel.
J Immunol, 2012 Nov 16; 189(12). PMID: 23152566    Free PMC article.
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
Margaret K Callahan, Jedd D Wolchok.
J Leukoc Biol, 2013 May 15; 94(1). PMID: 23667165    Free PMC article.
Highly Cited. Review.
Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.
Abbi L Engel, Guan-Cheng Sun, +6 authors, Hailing Lu.
Immunobiology, 2013 Jun 06; 218(12). PMID: 23735481    Free PMC article.
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
Jeffrey Weber, Omid Hamid, +8 authors, Jedd D Wolchok.
Cancer Immun, 2013 Jul 09; 13. PMID: 23833564    Free PMC article.
Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H Manjili, +3 authors, Xiang-Yang Wang.
Adv Cancer Res, 2013 Jul 23; 119. PMID: 23870514    Free PMC article.
Highly Cited. Review.
Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies.
Arta Monir Monjazeb, Anthony E Zamora, +3 authors, William J Murphy.
Front Oncol, 2013 Jul 31; 3. PMID: 23898464    Free PMC article.
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
Thomas John, Maud H W Starmans, +14 authors, Jonathan S Cebon.
PLoS One, 2013 Aug 13; 8(7). PMID: 23935846    Free PMC article.
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays.
Iole Macchia, Francesca Urbani, Enrico Proietti.
Biomed Res Int, 2013 Nov 07; 2013. PMID: 24195078    Free PMC article.
Regulatory T cells in colorectal cancer: from biology to prognostic relevance.
Dimitrios Mougiakakos.
Cancers (Basel), 2011 Jan 01; 3(2). PMID: 24212779    Free PMC article.
Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment.
Anne Gallois, Nina Bhardwaj.
Front Immunol, 2013 Dec 18; 4. PMID: 24339825    Free PMC article.
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
Shigehisa Kitano, Takemasa Tsuji, +7 authors, Jedd D Wolchok.
Cancer Immunol Res, 2014 Jan 08; 1(4). PMID: 24396833    Free PMC article.
Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells.
Evan W Newell, Mark M Davis.
Nat Biotechnol, 2014 Jan 21; 32(2). PMID: 24441473    Free PMC article.
Highly Cited. Review.
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Camilla Jandus, Kayluz Frias Boligan, +11 authors, Stephan von Gunten.
J Clin Invest, 2014 Feb 27; 124(4). PMID: 24569453    Free PMC article.
Highly Cited.
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Lidia Robert, Jennifer Tsoi, +11 authors, Antoni Ribas.
Clin Cancer Res, 2014 Mar 04; 20(9). PMID: 24583799    Free PMC article.
Highly Cited.
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.
Smita K Nair, Gabriel De Leon, +9 authors, Duane A Mitchell.
Clin Cancer Res, 2014 Mar 25; 20(10). PMID: 24658154    Free PMC article.
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma.
Jianda Yuan, Geoffrey Y Ku, +9 authors, Jedd D Wolchok.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829756    Free PMC article.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Donald Lawrence, +20 authors, David McDermott.
Cancer Immunol Res, 2014 May 20; 2(7). PMID: 24838938    Free PMC article.
Highly Cited.
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Yi-Chi M Kong, Jeffrey C Flynn.
Front Immunol, 2014 Jun 07; 5. PMID: 24904570    Free PMC article.
FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells.
Walter Moises Tobias Braga, Bruna Raphaeli da Silva, +5 authors, Gisele Wally Braga Colleoni.
Cancer Immunol Immunother, 2014 Aug 08; 63(11). PMID: 25099367    Free PMC article.
Molecular regulation of effector and memory T cell differentiation.
John T Chang, E John Wherry, Ananda W Goldrath.
Nat Immunol, 2014 Nov 15; 15(12). PMID: 25396352    Free PMC article.
Highly Cited. Review.
Vaccines versus immunotherapy: overview of approaches in deciding between options.
Angus G Dalgleish.
Hum Vaccin Immunother, 2015 Jan 28; 10(11). PMID: 25625932    Free PMC article.
Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
Rachel Lubong Sabado, Anna Pavlick, +22 authors, Nina Bhardwaj.
Cancer Immunol Res, 2015 Jan 31; 3(3). PMID: 25633712    Free PMC article.
Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience.
J Gao, Q He, +6 authors, P Sharma.
Oncogene, 2015 Feb 11; 34(43). PMID: 25659583    Free PMC article.
Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection.
Anders Boyd, Jorge R Almeida, +5 authors, Martin Larsen.
PLoS One, 2015 Jun 06; 10(6). PMID: 26046523    Free PMC article.
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
Maud Condomines, Jon Arnason, +3 authors, Michel Sadelain.
PLoS One, 2015 Jun 26; 10(6). PMID: 26110267    Free PMC article.
Discs Large Homolog 1 Splice Variants Regulate p38-Dependent and -Independent Effector Functions in CD8+ T Cells.
Oscar Silva, Jillian Crocetti, +2 authors, M Carrie Miceli.
PLoS One, 2015 Jul 18; 10(7). PMID: 26186728    Free PMC article.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Aaron P Rapoport, Edward A Stadtmauer, +32 authors, Carl H June.
Nat Med, 2015 Jul 21; 21(8). PMID: 26193344    Free PMC article.
Highly Cited.
Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery.
Jianbin Wang, Joshua J DeClercq, +5 authors, Michael C Holmes.
Nucleic Acids Res, 2015 Nov 04; 44(3). PMID: 26527725    Free PMC article.
The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
Vy Phan-Lai, Yushe Dang, +2 authors, Mary L Disis.
Clin Cancer Res, 2015 Dec 15; 22(9). PMID: 26660518    Free PMC article.
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.
Michael P Castro, Neal Goldstein.
J Immunother Cancer, 2015 Dec 18; 3. PMID: 26674132    Free PMC article.
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Claire F Friedman, Michael A Postow.
Curr Oncol Rep, 2016 Feb 29; 18(4). PMID: 26922327    Free PMC article.
Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.
Florian Wimmers, Erik H J G Aarntzen, +4 authors, I Jolanda M de Vries.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942087    Free PMC article.
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.
Holbrook E Kohrt, Paul C Tumeh, +33 authors, Cancer Immunotherapy Trials Network (CITN).
J Immunother Cancer, 2016 Mar 17; 4. PMID: 26981245    Free PMC article.
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
Cristina Maccalli, Diana Giannarelli, +5 authors, Michele Maio.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057436    Free PMC article.
SHP-1: the next checkpoint target for cancer immunotherapy?
H Angharad Watson, Sophie Wehenkel, James Matthews, Ann Ager.
Biochem Soc Trans, 2016 Apr 14; 44(2). PMID: 27068940    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.
Eleni Kotsiou, Jessica Okosun, +5 authors, Jeffrey K Davies.
Blood, 2016 Apr 23; 128(1). PMID: 27103745    Free PMC article.
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Alexander Martens, Kilian Wistuba-Hamprecht, +15 authors, Benjamin Weide.
Clin Cancer Res, 2016 May 14; 22(19). PMID: 27169993    Free PMC article.
Highly Cited.
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.
Marianna Sabatino, Jinhui Hu, +12 authors, Luca Gattinoni.
Blood, 2016 May 27; 128(4). PMID: 27226436    Free PMC article.
Highly Cited.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.
Weizhou Hou, Padma Sampath, Juan J Rojas, Steve H Thorne.
Cancer Cell, 2016 Jul 05; 30(1). PMID: 27374223    Free PMC article.
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Janet Kerstin Peper, Hans-Christian Bösmüller, +9 authors, Annette Staebler.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467910    Free PMC article.
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS.
Ornella Franzese, Belinda Palermo, +6 authors, Paola Nisticò.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467927    Free PMC article.
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.
Zhi-Chun Ding, Chufeng Liu, +10 authors, Gang Zhou.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471650    Free PMC article.
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.
Zhan Wang, Binghao Li, Yingqing Ren, Zhaoming Ye.
Front Immunol, 2016 Sep 30; 7. PMID: 27683579    Free PMC article.
Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Shu Wang, Jose Campos, +5 authors, Cristiana Guiducci.
Proc Natl Acad Sci U S A, 2016 Nov 02; 113(46). PMID: 27799536    Free PMC article.
Highly Cited.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
David Y Oh, Jason Cham, +5 authors, Lawrence Fong.
Cancer Res, 2016 Dec 30; 77(6). PMID: 28031229    Free PMC article.
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.
Jon Amund Kyte, Gustav Gaudernack, +7 authors, Martin Pule.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123886    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Precision medicine driven by cancer systems biology.
Fabian V Filipp.
Cancer Metastasis Rev, 2017 Mar 08; 36(1). PMID: 28265786    Free PMC article.
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs.
Aditya Arra, Holger Lingel, +6 authors, Monika C Brunner-Weinzierl.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344884    Free PMC article.
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R Ramjiawan, Arjan W Griffioen, Dan G Duda.
Angiogenesis, 2017 Apr 01; 20(2). PMID: 28361267    Free PMC article.
Highly Cited. Review.
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.
Stefanie Gross, Michael Erdmann, +12 authors, Beatrice Schuler-Thurner.
JCI Insight, 2017 Apr 20; 2(8). PMID: 28422751    Free PMC article.
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
Sacha Gnjatic, Vincenzo Bronte, +13 authors, Lisa H Butterfield.
J Immunother Cancer, 2017 May 19; 5. PMID: 28515944    Free PMC article.
Highly Cited. Review.
Intratumoral depletion of regulatory T cells using CD25-targeted photodynamic therapy in a mouse melanoma model induces antitumoral immune responses.
Dong Sun Oh, Heegon Kim, +4 authors, Heung Kyu Lee.
Oncotarget, 2017 May 26; 8(29). PMID: 28537894    Free PMC article.
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Anderly C Chüeh, Mun-Sem Liew, +8 authors, Thomas John.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088766    Free PMC article.
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.
Stefanie R Bailey, Michelle H Nelson, +9 authors, Chrystal M Paulos.
Nat Commun, 2017 Dec 08; 8(1). PMID: 29213079    Free PMC article.
Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.
Chungyong Han, Su-Jung Sim, +11 authors, Byoung S Kwon.
Nat Commun, 2018 Feb 03; 9(1). PMID: 29391449    Free PMC article.
Polyfunctionality of CD4+ T lymphocytes is increased after chemoradiotherapy of head and neck squamous cell carcinoma.
J Doescher, S Jeske, +6 authors, P J Schuler.
Strahlenther Onkol, 2018 Apr 18; 194(5). PMID: 29663037
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Remy Thomas, Ghaneya Al-Khadairi, +4 authors, Julie Decock.
Front Immunol, 2018 May 18; 9. PMID: 29770138    Free PMC article.
Highly Cited. Review.
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Janet Retseck, Alexis Nasr, +4 authors, Ahmad A Tarhini.
J Transl Med, 2018 Jul 06; 16(1). PMID: 29973204    Free PMC article.
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Todd A Triplett, Kendra C Garrison, +23 authors, George Georgiou.
Nat Biotechnol, 2018 Jul 17; 36(8). PMID: 30010674    Free PMC article.
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.
Arjan A van de Loosdrecht, Sandra van Wetering, +8 authors, Tanja D de Gruijl.
Cancer Immunol Immunother, 2018 Jul 25; 67(10). PMID: 30039426    Free PMC article.
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.
Sebastian Kobold, Stanislav Pantelyushin, Felicitas Rataj, Johannes Vom Berg.
Front Oncol, 2018 Aug 10; 8. PMID: 30090763    Free PMC article.
B cells and antibody production in melanoma.
Jessica Da Gama Duarte, Janique M Peyper, Jonathan M Blackburn.
Mamm Genome, 2018 Sep 05; 29(11-12). PMID: 30178304
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Wouter Ouwerkerk, Mirjam van den Berg, +2 authors, Rosalie M Luiten.
Melanoma Res, 2019 Mar 12; 29(5). PMID: 30855527    Free PMC article.
Systematic Review.
Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease.
Peter A Szabo, Hanna Mendes Levitin, +9 authors, Peter A Sims.
Nat Commun, 2019 Oct 19; 10(1). PMID: 31624246    Free PMC article.
Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation.
Hester J Scheffer, Anita G M Stam, +7 authors, Tanja D de Gruijl.
Oncoimmunology, 2019 Oct 28; 8(11). PMID: 31646081    Free PMC article.
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.
Chaofan Li, Bibo Zhu, +18 authors, Jie Sun.
Immunity, 2019 Sep 19; 51(3). PMID: 31533057    Free PMC article.
Highly Cited.
Therapeutic proteins.
Dimiter S Dimitrov.
Methods Mol Biol, 2012 Jun 28; 899. PMID: 22735943    Free PMC article.
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
Brenda De Keersmaecker, Sofie Claerhout, +5 authors, Kris Thielemans.
J Immunother Cancer, 2020 Mar 03; 8(1). PMID: 32114500    Free PMC article.
Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients.
Tara M Robinson, Gabrielle T Prince, +6 authors, B Douglas Smith.
Leuk Lymphoma, 2018 Apr 05; 59(12). PMID: 29616857    Free PMC article.
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells.
Sema Kurtulus, Asaf Madi, +10 authors, Ana C Anderson.
Immunity, 2019 Jan 13; 50(1). PMID: 30635236    Free PMC article.
Highly Cited.
Breast Tumor Cells Highly Resistant to Drugs Are Controlled Only by the Immune Response Induced in an Immunocompetent Mouse Model.
Paola Lasso, Mónica Llano Murcia, +3 authors, Susana Fiorentino.
Integr Cancer Ther, 2019 May 07; 18. PMID: 31056957    Free PMC article.
The B-side of Cancer Immunity: The Underrated Tune.
Anne Largeot, Giulia Pagano, +2 authors, Jerome Paggetti.
Cells, 2019 May 16; 8(5). PMID: 31086070    Free PMC article.
Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma.
Akiko Arakawa, Sigrid Vollmer, +5 authors, Jörg C Prinz.
Front Immunol, 2019 Jul 06; 10. PMID: 31275310    Free PMC article.
Polymorphic Region-Specific Antibody for Evaluation of Affinity-Associated Profile of Chimeric Antigen Receptor.
Chungyong Han, Beom K Choi, +10 authors, Byoung S Kwon.
Mol Ther Oncolytics, 2020 May 06; 17. PMID: 32368617    Free PMC article.
CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor.
Naoko Imai, Isao Tawara, +3 authors, Hiroaki Ikeda.
Cancer Sci, 2020 Apr 19; 111(6). PMID: 32304127    Free PMC article.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Annona muricata L.-Derived Polysaccharides as a Potential Adjuvant to a Dendritic Cell-Based Vaccine in a Thymoma-Bearing Model.
Woo Sik Kim, Jeong Moo Han, +3 authors, Eui-Baek Byun.
Nutrients, 2020 Jun 04; 12(6). PMID: 32486094    Free PMC article.
Edible Oxya chinensis sinuosa-Derived Protein as a Potential Nutraceutical for Anticancer Immunity Improvement.
Woo Sik Kim, Jeong Moo Han, +3 authors, Eui-Baek Byun.
Nutrients, 2020 Oct 28; 12(11). PMID: 33105813    Free PMC article.
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy.
Zili Gu, Candido G Da Silva, +2 authors, Luis J Cruz.
Pharmaceutics, 2020 Nov 08; 12(11). PMID: 33158166    Free PMC article.
Nanomaterial-Based Tumor Photothermal Immunotherapy.
Peng Xu, Feng Liang.
Int J Nanomedicine, 2020 Nov 28; 15. PMID: 33244232    Free PMC article.
No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma.
Stephanie L Goff, Paul F Robbins, Mona El-Gamil, Steven A Rosenberg.
J Immunother, 2009 Sep 16; 32(8). PMID: 19752745    Free PMC article.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, +10 authors, Steven A Rosenberg.
Science, 2014 May 09; 344(6184). PMID: 24812403    Free PMC article.
Highly Cited.
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Anastasia Mpakali, Efstratios Stratikos.
Cancers (Basel), 2021 Jan 08; 13(1). PMID: 33406696    Free PMC article.
Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression.
Jesse D Armitage, Hannah V Newnes, +2 authors, Jason Waithman.
Cells, 2021 Jan 07; 10(1). PMID: 33401460    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Varied functions of immune checkpoints during cancer metastasis.
Ali Safarzadeh, Mohsen Alizadeh, +7 authors, Nicola Silvestris.
Cancer Immunol Immunother, 2020 Sep 10; 70(3). PMID: 32902664    Free PMC article.
Cancer Vaccines: Antigen Selection Strategy.
Yue Zhao, Alexey V Baldin, +3 authors, Alexandr V Bazhin.
Vaccines (Basel), 2021 Jan 29; 9(2). PMID: 33503926    Free PMC article.
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Eun Hee Jung, Hee Ryeong Jang, +10 authors, Jong Seok Lee.
Thorac Cancer, 2021 Jan 19; 12(5). PMID: 33458968    Free PMC article.
Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Franziska K Krebs, Emily R Trzeciak, +6 authors, Andrea Tuettenberg.
Cancer Med, 2021 Jan 16; 10(5). PMID: 33449393    Free PMC article.
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Craig L Slingluff, Hassane M Zarour, +13 authors, Jedd D Wolchok.
Oncoimmunology, 2021 Apr 03; 10(1). PMID: 33796406    Free PMC article.
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Isabelle Magalhaes, Ingrid Kalland, +3 authors, Jonas Mattsson.
J Immunother, 2018 Jan 10; 41(2). PMID: 29315094    Free PMC article.
Analysis of LAGEs Family Gene Signature and Prognostic Relevance in Breast Cancer.
Hoang Dang Khoa Ta, Wan-Chun Tang, +7 authors, Chih-Yang Wang.
Diagnostics (Basel), 2021 May 01; 11(4). PMID: 33921749    Free PMC article.
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.
Spyridoula Vasileiou, Premal D Lulla, +19 authors, George Carrum.
J Clin Oncol, 2021 Jan 29; 39(13). PMID: 33507803    Free PMC article.
Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.
Yoshinobu Ichiki, Takashi Fukuyama, +8 authors, Tsuyoshi Ishida.
Transl Cancer Res, 2022 Feb 05; 10(12). PMID: 35116371    Free PMC article.
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Nina Bhardwaj, Philip A Friedlander, +31 authors, Steven P Fling.
Nat Cancer, 2020 Dec 01; 1(12). PMID: 35121932
A genome-scale screen for synthetic drivers of T cell proliferation.
Mateusz Legut, Zoran Gajic, +11 authors, Neville E Sanjana.
Nature, 2022 Mar 18; 603(7902). PMID: 35296855
Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
Andrea Aran, Laia Garrigós, +2 authors, Mercè Martí.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406543    Free PMC article.